{"disease":{"id":"acromegaly","name":"Acromegaly","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":8,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"lanreotide","indication_name":"Acromegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Somatuline Depot","generic_name":"LANREOTIDE","company_name":"Ipsen Pharma","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":10,"revenue":"1200","mechanism":"Somatuline Depot works by mimicking the natural hormone somatostatin to block the production of excess growth hormone."},{"drug_id":"lanreotide","indication_name":"Acromegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Somatuline Depot","generic_name":"LANREOTIDE","company_name":"Ipsen Pharma","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":10,"revenue":"1200","mechanism":"Somatuline Depot works by mimicking the natural hormone somatostatin to block the production of excess growth hormone."},{"drug_id":"octreotide","indication_name":"Acromegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandostatin","generic_name":"OCTREOTIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":75,"revenue":"305","mechanism":"Sandostatin works by mimicking the natural hormone somatostatin to inhibit the release of various hormones and growth factors."},{"drug_id":"somavert","indication_name":"Acromegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trovert","generic_name":"somavert","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Growth Hormone Receptor Antagonist","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"lisuride","indication_name":"Acromegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisurid","generic_name":"LISURIDE","company_name":"","drug_phase":"phase_3","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"lisuride","quality_score":null,"revenue":null,"mechanism":"Lisuride works by binding to and activating the alpha-2A adrenergic receptor, which helps to regulate various physiological processes."},{"drug_id":"paltusotine","indication_name":"acromegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palsonify","generic_name":"PALTUSOTINE","company_name":"Crinetics","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Palsonify works by binding to and inhibiting a specific protein involved in the regulation of growth hormone production."},{"drug_id":"bromocriptin","indication_name":"Acromegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bromocriptin","company_name":"University Hospital, Bonn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pegvisomant","indication_name":"Acromegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trovert","generic_name":"PEGVISOMANT","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Growth Hormone Receptor Antagonist","quality_score":48,"revenue":null,"mechanism":"Pegvisomant works by binding to the growth hormone receptor, blocking the action of growth hormone and preventing excessive growth and cell division."},{"drug_id":"bromocriptine","indication_name":"Acromegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parlodel","generic_name":"BROMOCRIPTINE","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Ergot Derivative","quality_score":51,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00461188","title":"Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Barts & The London NHS Trust","has_results":false},{"nct_id":"NCT00001595","title":"An Investigation of Pituitary Tumors and Related Hypothalmic Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT03158090","title":"The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research","phase":"","overall_status":"RECRUITING","enrollment_count":1965,"lead_sponsor_name":"Ginkgo Leaf Center for Rare Disorders","has_results":false},{"nct_id":"NCT03474601","title":"Seoul National University Pituitary Disease Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1600,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT02371057","title":"Acromegaly & Sleep Apnoea","phase":"","overall_status":"COMPLETED","enrollment_count":653,"lead_sponsor_name":"The Leeds Teaching Hospitals NHS Trust","has_results":false},{"nct_id":"NCT04349839","title":"ACRODAT Prospective Evaluation Study","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT02020967","title":"Programme of Acromegaly Screening in Patients With Associated Somatic Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":367,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT00600886","title":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":358,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01794793","title":"Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":337,"lead_sponsor_name":"RECORDATI GROUP","has_results":true},{"nct_id":"NCT04844164","title":"Vitamin D Metabolism in Patients With Endocrine Disorders","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":261,"lead_sponsor_name":"Endocrinology Research Centre, Moscow","has_results":false},{"nct_id":"NCT00658879","title":"Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan","phase":"","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04860037","title":"Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT02060383","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":249,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01504399","title":"Rhinological Outcomes in Endonasal Pituitary Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"St. Joseph's Hospital and Medical Center, Phoenix","has_results":false},{"nct_id":"NCT04529356","title":"The TMS Treatment for Postoperative Headache in GH Tumor","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT01137682","title":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03613623","title":"Acromegaly: Patient And Physician Perspectives","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Tulane University","has_results":false},{"nct_id":"NCT04125836","title":"A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Camurus AB","has_results":false},{"nct_id":"NCT05431803","title":"Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China","phase":"","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT02354508","title":"Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03673761","title":"Muscle in Acromegaly and Cushing's Syndrome","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT00001981","title":"The Treatment and Natural History of Acromegaly","phase":"","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT04066569","title":"Reproducibility and Utility of OGTT in Acromegaly","phase":"NA","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06607666","title":"Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands","phase":"","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05131100","title":"Korean Regulatory Post Marketing Surveillance for Somavert","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03439709","title":"Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03042026","title":"Developing a Simple Recognition System of Acromegaly","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03225040","title":"Bone MicroArchitecture in Acromegaly","phase":"","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03571594","title":"A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":76,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01538966","title":"Acromegaly Combination Treatment Study","phase":"NA","overall_status":"TERMINATED","enrollment_count":76,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":true},{"nct_id":"NCT04076462","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Camurus AB","has_results":false},{"nct_id":"NCT03401008","title":"Buccodental Manifestations in Patients With Acromegaly","phase":"","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT02296216","title":"Late Effects of Radiosurgery on Acromegaly Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT05069324","title":"PegvisOMant and the Immune SystEm (PROMISE)","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT06949891","title":"KETOgenic Diet Therapy in Patients With ACROmegaly","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT07037420","title":"ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05761431","title":"A Single-dose Study of Octreotide Injection in Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT03789656","title":"An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Crinetics Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT03548415","title":"Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04138537","title":"Olfactory Function and Olfactory Bulb Volume in Acromegaly Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Bezmialem Vakif University","has_results":false},{"nct_id":"NCT03967249","title":"Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05752825","title":"Acromegaly: Balance, Falls and Fracture Risk","phase":"","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Christian Alexander H Rosendal","has_results":false},{"nct_id":"NCT04522180","title":"A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07306325","title":"Ultrasound in Predicting Difficult Intubation in Acromegaly Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Başakşehir Çam & Sakura City Hospital","has_results":false},{"nct_id":"NCT01673646","title":"Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06372652","title":"A Phase 1 Study of TE-8214 Solution in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Immunwork, Inc.","has_results":false},{"nct_id":"NCT00171730","title":"An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05964712","title":"Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Istituto Auxologico Italiano","has_results":false},{"nct_id":"NCT07100587","title":"Ketogenic vs. Mediterranean Diet on Metabolic and Hormonal Parameters in Patients With Active Acromegaly","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"University of Palermo","has_results":false},{"nct_id":"NCT03807076","title":"Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor","phase":"NA","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"University of Copenhagen","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}